Skip to main content
Eligibility
for females ages 18 years and up
Healthy Volunteers
healthy people welcome
Location
at San Francisco, California
Dates
study started
Principal Investigator

Description

Summary

Excessive bleeding after dilation and evacuation (D&E) requiring interventions is common, occurring in approximately 30% of cases at one large abortion-providing clinic. Uterotonic prophylaxis at the time of D&E, particularly with methylergonovine maleate (MM), is a common practice among D&E providers despite nearly no evidence for its efficacy. Finding ways to decrease excessive bleeding after D&E has the potential both to improve patient safety and to reduce costs of provider-initiated interventions. The investigators propose a randomized, controlled trial to investigate the efficacy of MM prophylaxis versus placebo in decreasing excessive bleeding measured by a composite outcome among women undergoing D&E at 20 to 24 weeks.

Keywords

Hemorrhage Methylergonovine

Eligibility

For females ages 18 years and up

Inclusion Criteria:

  • Between 20 wks 0 days gestation and 24 wks 0 days gestation
  • English or Spanish speaking
  • BP before injection 140/90 or below
  • 18 years old or over

Location

  • SFGH Women's Options Center accepting new patients
    San Francisco, California, 94110, USA

Details

Status
accepting new patients
Start Date
Sponsor
University of California, San Francisco
ID
NCT02408965
Phase
Phase 4
Lead Scientist
Jennifer Kerns
Study Type
Interventional
Last Updated
May 2016
I'm interested in this study!